Novo Nordisk submitted approval applications to the FDA and EMA on November 13, 2026, for etavopivat, a once-daily oral therapy for sickle cell disease in patients aged 12 and older. Acquired in a $1 billion buyout of Forma Therapeutics in 2022, etavopivat reduced annual painful vaso-occlusive crises by 27% and delayed the first crisis by four months in Phase 3 trials. Regulators are expected to act in 2027 on the drug, which Novo Nordisk views as a potential future blockbuster.
Story comments
Loading comments…